ArticleArchives of dermatological research2025
Plasma irisin levels in newly diagnosed leprosy patients: a case-control study.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy is a granulomatous disease affecting the skin, mucous membrane, and peripheral nerves. Irisin, a novel protein, has been associated with several inflammatory and metabolic diseases and has been demonstrated in peripheral nerve cells. The objective of this study was to compare the plasma irisin levels of newly diagnosed leprosy patients with those of healthy individuals while also assessing the role of irisin in the pathogenesis of leprosy. This case-control study was conducted between January 2024 and July 2024 and compared 29 newly diagnosed leprosy patients with 29 healthy controls. The participants' demographic information and disease history, such as the duration of the disease and whether any additional family members had leprosy, were documented. The subjects' serum irisin levels were quantified via enzyme-linked immunosorbent assay (ELISA). The serum level of irisin was significantly lower in the patient group than in the control group (p value < 0.001). We found lower Irisin levels in leprosy patients than healthy controls, suggesting potential as role as a biomarker for leprosy. Further investigations, involving a large sample sized assessed both during and after therapy, are necessary to clarify the function and predictive significance of irisin in leprosy.
Indexed as
Identifiers
39945874What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.